Glossary
Patient-specific prescription: the condition the 503A exemption is built on
A patient-specific prescription is a valid prescription order written for an identified individual patient, and it is the condition on which the federal exemption at 21 U.S.C. § 353a hangs. The exemption attaches to the act of compounding for that one patient rather than to the pharmacy as an institution, which is why a licensed pharmacy does not carry the exemption around with everything it makes. State pharmacy rules restate the same requirement in their own words, several of them as an express default with narrow exceptions.
The condition, in the statute’s own words
Section 353a does not begin by describing a kind of pharmacy. It begins by naming three federal requirements that stop applying, and the condition attached to them:
Sections 351(a)(2)(B), 352(f)(1), and 355 of this title shall not apply to a drug product if the drug product is compounded for an identified individual patient based on the receipt of a valid prescription order or a notation, approved by the prescribing practitioner, on the prescription order that a compounded product is necessary for the identified patient
The grammar is the point. "Shall not apply to a drug product … if the drug product is compounded for an identified individual patient" conditions the exemption on the individual preparation, not on the compounder. A 503A pharmacy holds a state licence; it does not hold the exemption in a way that travels to everything on its shelves.
How state rules restate it
Several boards write the same requirement as the default position and then carve out from it. Illinois states it in one sentence at the head of its office-use rule:
A pharmacy may only dispense compounded drugs pursuant to a valid patient-specific prescription, except as provided in this Section.
North Carolina opens its compounding rule the same way — a compounded preparation may be dispensed to a patient "only pursuant to a prescription that is valid and complies with all requirements of the law" — and then allows preparation ahead of the order only on an established history, with release still conditioned on a valid order for an individual patient.
The one narrow exception, and what it is not
Section 353a(a)(2) permits compounding "in limited quantities before the receipt of a valid prescription order," on an established history of receiving such orders. That is anticipatory compounding, and it changes the timing rather than the requirement: the stock is still released against a prescription naming a patient.
It is therefore not authority to supply a practice with cabinet stock. Stock that names no patient is office use, which is outside § 353a by the section’s own terms and which at federal level runs through a 503B outsourcing facility instead.
The full treatment — who may write the order, where the requirement stops, and why a state permission does not displace it — is in does a compounded drug need a patient-specific prescription. The two federal bargains are compared in 503A vs 503B.